Literature DB >> 16078115

CHEK2 mutations in primary glioblastomas.

Satu-Leena Sallinen, Tarja Ikonen, Hannu Haapasalo, Johanna Schleutker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16078115     DOI： 10.1007/s11060-005-5953-7

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  29 in total

1.  A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.

Authors:  Pia Vahteristo; Jirina Bartkova; Hannaleena Eerola; Kirsi Syrjäkoski; Salla Ojala; Outi Kilpivaara; Anitta Tamminen; Juha Kononen; Kristiina Aittomäki; Päivi Heikkilä; Kaija Holli; Carl Blomqvist; Jiri Bartek; Olli-P Kallioniemi; Heli Nevanlinna
Journal:  Am J Hum Genet       Date:  2002-07-28       Impact factor: 11.025

2.  Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors.

Authors:  Carl W Miller; Takayuki Ikezoe; Utz Krug; Wolf-K Hofmann; Sigal Tavor; Vijaya Vegesna; Kunihiro Tsukasaki; Seisho Takeuchi; H Phillip Koeffler
Journal:  Genes Chromosomes Cancer       Date:  2002-01       Impact factor: 5.006

3.  Characterization of tumor-associated Chk2 mutations.

Authors:  X Wu; S R Webster; J Chen
Journal:  J Biol Chem       Date:  2000-10-26       Impact factor: 5.157

4.  Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro.

Authors:  S Matsuoka; G Rotman; A Ogawa; Y Shiloh; K Tamai; S J Elledge
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

5.  Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples.

Authors:  M Tanner; D Gancberg; A Di Leo; D Larsimont; G Rouas; M J Piccart; J Isola
Journal:  Am J Pathol       Date:  2000-11       Impact factor: 4.307

6.  Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility.

Authors:  Mieke Schutte; Sheila Seal; Rita Barfoot; Hanne Meijers-Heijboer; Marijke Wasielewski; D Gareth Evans; Diana Eccles; Carel Meijers; Frans Lohman; Jan Klijn; Ans van den Ouweland; P Andrew Futreal; Katherine L Nathanson; Barbara L Weber; Douglas F Easton; Michael R Stratton; Nazneen Rahman
Journal:  Am J Hum Genet       Date:  2003-02-27       Impact factor: 11.025

7.  Aberrant p53 expression in astrocytic neoplasms of the brain: association with proliferation.

Authors:  H Haapasalo; J Isola; P Sallinen; H Kalimo; H Helin; I Rantala
Journal:  Am J Pathol       Date:  1993-05       Impact factor: 4.307

8.  The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.

Authors:  Rogier A Oldenburg; Karin Kroeze-Jansema; Jaennelle Kraan; Hans Morreau; Jan G M Klijn; Nicoline Hoogerbrugge; Marjolein J L Ligtenberg; Christi J van Asperen; Hans F A Vasen; Carel Meijers; Hanne Meijers-Heijboer; Truuske H de Bock; Cees J Cornelisse; Peter Devilee
Journal:  Cancer Res       Date:  2003-12-01       Impact factor: 12.701

9.  CHEK2 variant I157T may be associated with increased breast cancer risk.

Authors:  Outi Kilpivaara; Pia Vahteristo; Jacob Falck; Kirsi Syrjäkoski; Hannaleena Eerola; Douglas Easton; Jirina Bartkova; Jiri Lukas; Päivi Heikkilä; Kristiina Aittomäki; Kaija Holli; Carl Blomqvist; Olli-Pekka Kallioniemi; Jiri Bartek; Heli Nevanlinna
Journal:  Int J Cancer       Date:  2004-09-10       Impact factor: 7.396

10.  Analysis of the NF2 tumor-suppressor gene and of chromosome 22 deletions in gliomas.

Authors:  K Hoang-Xuan; P Merel; F Vega; J P Hugot; P Cornu; J Y Delattre; M Poisson; G Thomas; O Delattre
Journal:  Int J Cancer       Date:  1995-02-08       Impact factor: 7.396
View more
  8 in total

1.  Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas.

Authors:  Massimo Squatrito; Cameron W Brennan; Karim Helmy; Jason T Huse; John H Petrini; Eric C Holland
Journal:  Cancer Cell       Date:  2010-12-14       Impact factor: 31.743

Review 2.  Role of CHK2 in cancer development.

Authors:  Rosario Perona; Verónica Moncho-Amor; Rosario Machado-Pinilla; Cristóbal Belda-Iniesta; Isabel Sánchez Pérez
Journal:  Clin Transl Oncol       Date:  2008-09       Impact factor: 3.405

Review 3.  CHEK2 (∗) 1100delC Mutation and Risk of Prostate Cancer.

Authors:  Victoria Hale; Maren Weischer; Jong Y Park
Journal:  Prostate Cancer       Date:  2014-11-06

4.  Is CHEK2 a moderate-risk breast cancer gene or the younger sister of Li-Fraumeni?

Authors:  Dilanka L De Silva; Ingrid Winship
Journal:  BMJ Case Rep       Date:  2020-09-07

5.  The First Case Report of a Patient With Oligodendroglioma Harboring CHEK2 Germline Mutation.

Authors:  Xueen Li; Hao Xue; Ningning Luo; Tiantian Han; Mengmeng Li; Deze Jia
Journal:  Front Genet       Date:  2022-02-23       Impact factor: 4.599

6.  Aberrant signaling pathways in glioma.

Authors:  Mitsutoshi Nakada; Daisuke Kita; Takuya Watanabe; Yutaka Hayashi; Lei Teng; Ilya V Pyko; Jun-Ichiro Hamada
Journal:  Cancers (Basel)       Date:  2011-08-10       Impact factor: 6.639

7.  Germline rearrangements in families with strong family history of glioma and malignant melanoma, colon, and breast cancer.

Authors:  Ulrika Andersson; Carl Wibom; Kristina Cederquist; Steina Aradottir; Ake Borg; Georgina N Armstrong; Sanjay Shete; Ching C Lau; Matthew N Bainbridge; Elizabeth B Claus; Jill Barnholtz-Sloan; Rose Lai; Dora Il'yasova; Richard S Houlston; Joellen Schildkraut; Jonine L Bernstein; Sara H Olson; Robert B Jenkins; Daniel H Lachance; Margaret Wrensch; Faith G Davis; Ryan Merrell; Christoffer Johansen; Siegal Sadetzki; Melissa L Bondy; Beatrice S Melin
Journal:  Neuro Oncol       Date:  2014-04-09       Impact factor: 12.300

8.  FGFR1 tyrosine kinase domain duplication in pilocytic astrocytoma with anaplasia.

Authors:  Leomar Y Ballester; Marta Penas-Prado; Norman E Leeds; Jason T Huse; Gregory N Fuller
Journal:  Cold Spring Harb Mol Case Stud       Date:  2018-04-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.